免責聲明: 本站彙整 FDA、ClinicalTrials.gov、PubMed、SEC EDGAR 等官方公開資料,僅供一般參考,不構成醫療建議、診斷、治療建議或投資建議。

FDA 510(k)

Gammex® PI Plus Glove-in-Glove™ 系統已經通過測試,適合與化學治療藥物使用

K 號:K213289 · 2023-05-26

決定日期2023-05-26
產品代碼KGO
諮詢委員會SU 請提供完整的描述文本,以便我進行翻譯。
決定相當於

器材摘要

Gammex® PI Plus Glove-in-Glove™ System Tested For Use with Chemotherapy Drugs is the device name listed in this FDA 510(k) record. The listed applicant is Ansell Healthcare Products, LLC. It received FDA 510(k) clearance on 2023-05-26 under 510(k) number K213289. The device is classified under product code KGO. It was reviewed by the SU advisory panel. FDA Decision: Substantially Equivalent.

常見問題

What is the Gammex® PI Plus Glove-in-Glove™ System Tested For Use with Chemotherapy Drugs?

Gammex® PI Plus Glove-in-Glove™ System Tested For Use with Chemotherapy Drugs is a medical device that received FDA 510(k) clearance on 2023-05-26. The listed applicant is Ansell Healthcare Products, LLC. The 510(k) number is K213289.

When did Gammex® PI Plus Glove-in-Glove™ System Tested For Use with Chemotherapy Drugs receive FDA 510(k) clearance?

Gammex® PI Plus Glove-in-Glove™ System Tested For Use with Chemotherapy Drugs received FDA 510(k) clearance on 2023-05-26, under 510(k) number K213289.

Who is the listed applicant for Gammex® PI Plus Glove-in-Glove™ System Tested For Use with Chemotherapy Drugs?

The FDA 510(k) record lists Ansell Healthcare Products, LLC as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Gammex® PI Plus Glove-in-Glove™ System Tested For Use with Chemotherapy Drugs?

The FDA product code for Gammex® PI Plus Glove-in-Glove™ System Tested For Use with Chemotherapy Drugs is KGO.

相關臨床試驗

相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係,請查閱連結的官方來源。

其他以 Ansell Healthcare Products, LLC 為申請人之記錄

相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係,請查閱連結的官方來源。

查看所有 14 項裝置 →

相關器械(代碼:KGO)

相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係,請查閱連結的官方來源。

官方來源

在 FDA 資料庫中查看 →

資料來源為 FDA Open API。如需最新且權威的資訊,請始終參閱官方記錄。

↑